RxAll

RxAll Inc. is a health information technology and big-data startup focused on reducing counterfeit and substandard medicines. Its business combines drug-authentication hardware, software for pharmacy operations, and medicine-ordering and delivery services. The company works with pharmaceutical regulators, hospitals, pharmacies, patients, and other stakeholders to improve the identification and distribution of verified medicines. RxAll was established in 2016 by Adebayo Alonge, Amy Kao, and Wei Liu, who were associated with Yale University and the Yale School of Management. The company’s origin was closely connected to Alonge’s personal experience with counterfeit medicine: in 2005, while in Nigeria, he nearly died after taking fake salbutamol tablets. That experience helped shape RxAll’s focus on making medicine verification more accessible and useful in markets where counterfeit pharmaceuticals pose a serious public-health risk. The company’s principal technology is RxScanner, a handheld drug-authentication device. It uses artificial-intelligence-enabled spectroscopy to examine a medicine’s molecular fingerprint and provide an authenticity result through a mobile application. The system is designed to function even when an internet connection is unavailable, an important feature for facilities and regulators operating in environments with limited connectivity. RxScanner is intended for use by patients, pharmacies, hospitals, pharmaceutical companies, and government drug-regulatory agencies. It can also support record keeping, reduce the administrative burden of inspection, and generate evidence that may assist enforcement against suppliers of fraudulent medicines. Pilot or reported deployments have included Nigeria, Kenya, and India. RxAll has also developed RxAll POS, pharmacy point-of-sale and management software intended to automate operational processes for pharmacies in growth markets. A further offering, RxAll Delivered, provides an online ordering and delivery platform through which pharmacies and patients can obtain verified medicines for offline delivery, including at wholesale prices. Together, these products reflect a broader strategy: combine authentication at the product level with digital tools for inventory, commerce, and distribution. The company encountered a significant early financing challenge in the first quarter of 2017, when it came close to running out of cash. The founding team continued operating while seeking additional support. According to the available account, Alonge and Kao subsequently raised approximately $1 million through grants and bootstrapped funds associated with the Nigerian government, the Yale startup ecosystem, Merck, Villgro, and other support networks. The available source does not provide a complete financing history or ownership structure. RxAll has reported market entry or activity across parts of Africa, Southeast Asia, and the Americas. Its stated or reported geographic footprint includes Kenya and Uganda in East Africa; Nigeria and Ghana in West Africa; Myanmar, Malaysia, and Singapore in Southeast Asia; and Canada, the United States, and Colombia in the Americas. The company received the 2019 BNP Paribas Group deep-tech award in the Hello Tomorrow competition, with a stated prize value of €100,000. Current corporate status, headquarters, leadership structure, revenue, and ownership are not established by the supplied reference material.

RxAll was founded on January 1, 2016, by Adebayo Alonge, Amy Kao, and Wei Liu, graduates or affiliates of Yale University’s Yale School of Management. Its founding purpose was to address the public-health and supply-chain problems created by counterfeit and unverified medicines. The company’s concept was strongly influenced by Alonge’s experience in Nigeria in 2005, when he nearly died after taking counterfeit salbutamol tablets. That incident provided a personal rationale for developing a practical way to distinguish genuine medicines from fraudulent products. From its early stage, RxAll presented itself as more than a conventional pharmaceutical retailer. It sought to provide technology for patients and healthcare organizations while also supporting regulators and pharmaceutical suppliers. Its main product, RxScanner, was designed as a portable drug-authentication instrument using artificial-intelligence-enabled spectroscopy. Rather than relying only on packaging or serial numbers, the device analyzes a medicine’s molecular characteristics and returns an authentication result through a mobile application. Its reported offline capability was intended to make the system usable in hospitals, pharmacies, and regulatory settings where internet access may be unreliable. RxScanner was also designed to generate operational benefits for public authorities. In addition to helping identify suspect medicines, the system could improve inspection records, reduce manual administrative work, and support investigations and prosecutions involving counterfeit-drug networks. Reported pilot or use locations included Nigeria, Kenya, and India, with the broader product described as applicable to country-level drug regulators, hospitals, pharmacies, and pharmaceutical companies. The company faced an early financial and operational test in the first quarter of 2017, when it nearly exhausted its available cash. The founders continued running the business while raising additional resources. Adebayo Alonge and Amy Kao were reported to have secured roughly $1 million through grants and bootstrapped funds connected with the Nigerian government, Yale’s startup ecosystem, Merck, Villgro, and other support organizations. The supplied material does not establish whether this amount represented equity investment, grants alone, or a mixture of financing and in-kind support, and it does not provide a full capitalization history. RxAll subsequently broadened its product strategy. RxAll POS was developed as pharmacy point-of-sale and management software, intended to automate pharmacy administration in growth markets. RxAll Delivered added a commerce and logistics component, enabling pharmacies and patients to order verified medicines online for offline delivery, reportedly at wholesale prices. These offerings complemented RxScanner by addressing not only whether a medicine was authentic, but also how pharmacies manage stock and how verified products move to end users. The company’s reported geographic expansion covered multiple regions. In Africa, the cited markets included Kenya and Uganda in East Africa and Nigeria and Ghana in West Africa. In Southeast Asia, the cited footprint included Myanmar, Malaysia, and Singapore. In the Americas, the company reported entry into Canada, the United States, and Colombia. The available material does not distinguish consistently between commercial operations, pilots, partnerships, or market-entry plans in each country. In 2019, RxAll won the BNP Paribas Group deep-tech award associated with the Hello Tomorrow competition for technology innovators. The award was reported as being worth €100,000 and provided external recognition of the company’s technical approach to pharmaceutical authentication. Beyond this award, the supplied sources do not provide reliable information on later funding, acquisitions, revenue, public listing, current executives, headquarters, or present operating status. RxAll is therefore best described from the available evidence as a health-information and pharmaceutical-authentication startup whose products combine spectroscopy, artificial intelligence, pharmacy software, and medicine delivery.

• 2019

  Wins BNP Paribas Group deep-tech award

  [1]RxAllen.wikipedia.org

  RxAll won the BNP Paribas Group deep-tech award in the Hello Tomorrow competition, reported as carrying a €100,000 prize.

• 2017

  Early financing challenge and fundraising

  [1]RxAllen.wikipedia.org

  The startup nearly ran out of cash in the first quarter, then raised approximately $1 million through grants and bootstrapped support associated with government, university, corporate, and startup networks.

• 2016

  RxAll is established

  [1]RxAllen.wikipedia.org

  Adebayo Alonge, Amy Kao, and Wei Liu established RxAll on January 1, 2016, with a focus on medicine authentication and access to verified drugs.

• 2005

  Founder experiences counterfeit-medicine harm

  [1]RxAllen.wikipedia.org

  Adebayo Alonge nearly died in Nigeria after taking counterfeit salbutamol tablets, an experience that later influenced RxAll’s founding mission.

A health-technology platform positioned around medicine authentication, counterfeit-drug risk reduction, pharmacy digitization, and access to verified pharmaceuticals.

• Drug authentication device

  RxScanner

  RxScanner is a handheld medicine-authentication device that uses AI-enabled spectroscopy to analyze a drug’s molecular fingerprint. Results are delivered through a mobile application, and the system is designed to operate without an internet connection. It is intended for patients, pharmacies, hospitals, pharmaceutical companies, and drug-regulatory agencies. Besides helping identify counterfeit products, the device is designed to improve inspection records, reduce administrative workload, and support enforcement activity. Pilot or reported use has included Nigeria, Kenya, and India.

• Pharmacy management software

  RxAll POS

  RxAll POS is point-of-sale and pharmacy-management software intended to automate operational processes for pharmacies in growth markets. The supplied material identifies it as part of RxAll’s broader effort to digitize medicine inventory and pharmacy operations, but does not specify its complete feature set, commercial release date, or current availability.

• Medicine ordering and delivery platform

  RxAll Delivered

  RxAll Delivered is an online ordering and offline-delivery platform for verified medicines. It is designed to let pharmacies and patients order pharmaceutical products, reportedly at wholesale prices, while connecting the transaction to RxAll’s emphasis on medicine verification. The supplied material does not establish the platform’s current availability, logistics partners, or regulatory structure in each market.

• 2017

  Continue operations during an early cash shortageStrategy

  Background

  RxAll reportedly faced a near-exhaustion of cash during the first quarter of 2017.

  Action taken

  The founding team continued operating while raising grants and bootstrapped funds from public, university, corporate, and startup-support networks.

  Aftermath

  The company reportedly raised approximately $1 million in combined support, although the available source does not provide a detailed breakdown.

  Reported grants and bootstrapped funds. Approximately $1 million raised (2017)

  Source

• 2016

  Focus on technology-assisted medicine authenticationStrategy

  Background

  The founders created RxAll in response to the public-health risks associated with counterfeit medicines and the limitations of conventional verification and enforcement processes.

  Action taken

  RxAll developed a product strategy centered on portable spectroscopy, artificial intelligence, mobile verification, and tools for regulators, pharmacies, hospitals, and patients.

  Aftermath

  The strategy led to RxScanner and later expanded into pharmacy-management software and verified-medicine ordering and delivery.

  Source

1. 1RxAllen.wikipedia.org